A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06276933 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Camrelizumab

Interventions

DRUG: Camrelizumab + chemotherapy+Thalidomide
DRUG: Camrelizumab + chemotherapy+placebo

Sponsor

Tongji University

Collaborators

[object Object]